Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02333071 · ClinicalTrials.gov registry record · Phase 3
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
A Phase 3 study, sponsored by Palatin Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 723
- Enrollment target
NCT02333071: Completed Phase 3 study, sponsored by Palatin Technologies.
NCT02333071 is a Phase 3 study that has completed, run by Palatin Technologies. The registered enrollment target is 723 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02333071, a Phase 3 study, has completed, sponsored by Palatin Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 723 participants
- Enrollment target
Study Summary
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.
Primary Outcome
As measured by change from baseline to end-of-study in the desire domain from the FSFI (Question Q1 and Q2), 28-day recall, co-primary endpoint - FSFI desire domain. FSFI = Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. Its six subscales assess desire, arousal, lubrication, orgasm, satisfaction, and pain, by summing individual items that comprise the subscale and multiplying the sum by a factor, resulting in a score r
Interventions
- OTHER Placebo
- DRUG Bremelanotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 723 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-06-30 |
| Phase | Phase 3 |
What the finished NCT02333071 record still lists
NCT02333071 is an interventional study that assigns participants to a tested intervention. The registered 723 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02333071 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02333071 about?
NCT02333071 is a clinical study titled "1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder". A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal f...
What is the current status of trial NCT02333071?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 723 participants. The study started on 2014-12. Estimated completion is 2017-06-30.
What interventions are being tested in trial NCT02333071?
The interventions under investigation include: Placebo (OTHER), Bremelanotide (DRUG).
Who is sponsoring clinical trial NCT02333071?
This trial is sponsored by Palatin Technologies, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02333071's enrollment target sits among peer trials
723 492nd of 2000 higher than 1,507 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06641466 · 723 participants · Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
- NCT07088068 · 723 participants · Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
- NCT06664619 · 724 participants · Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
- NCT06116149 · 722 participants · NA
Strategies for Implementing a Postpartum Lifestyle Intervention in WIC Clinics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia